# IT and IV Lentiviral Gene Therapy for X-ALD

> **NCT03727555** · NA · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 30 (estimated)

## Conditions studied

- X-linked Adrenoleukodystrophy

## Interventions

- **GENETIC:** Intrathecal and intravenous LV gene therapy

## Key facts

- **NCT ID:** NCT03727555
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03727555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03727555, "IT and IV Lentiviral Gene Therapy for X-ALD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03727555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*